Expert Interviews

Panelists discuss strategies for patient education and monitoring hyperglycemia with PI3K inhibitors, including pre-treatment screening, baseline assessments, early recognition of adverse events, and supportive care measures such as dietary modifications, with Ms. Harrington sharing practical approaches and helpful resources; Dr Isaacs comments on potential differences in adverse event management, particularly hyperglycemia, between inavolisib, capivasertib, and alpelisib, offering practical advice for oncologists; and Dr Kaklamani explores how the varying safety profiles of these agents may influence treatment selection and sequencing, including the potential for inavolisib to become standard of care in the first-line PIK3CA-mutant setting and how this will affect PI3K inhibitor sequencing in later treatment lines.

Panelists discuss how clinicians should weigh the decision between initiating treatment with erythropoiesis-stimulating agents (ESAs) vs luspatercept in patients with myelodysplastic syndromes.

Panelists discuss how a third-line approach for a 54-year-old patient treated with a tucatinib-based regimen involves careful consideration of prior treatment responses, comorbidities, and the potential benefits of combining tucatinib with capecitabine and trastuzumab to improve outcomes in HER2+ metastatic breast cancer.

Panelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management, and the multidisciplinary care team in supporting patients through home-based care and active participation in their treatment journey.

Panelists discuss resources and strategies to help patients and caregivers cope with the initial shock of a paroxysmal nocturnal hemoglobinuria (PNH) diagnosis, emphasizing critical points during the first consultation, and explore how Brandi communicated her treatment preferences to her care team, reflecting on her sense of inclusion in the decision-making process and areas for improvement.

Panelists discuss how talquetamab demonstrates superior efficacy compared with physician-chosen treatments for patients with heavily pretreated multiple myeloma, with improved progression-free survival and response rates.

Panelists discuss how the MEDALIST and IMerge trials provide crucial insights into novel therapeutic approaches for treating myelodysplastic syndromes.

A panelist discusses how managing resistance mechanisms and toxicity profiles and identifying optimal sequencing strategies remain key challenges in treating EGFR-mutated metastatic non–small cell lung cancer despite advances in targeted therapies.

Panelists discuss how recent pivotal trials like PERSEUS and CASSIOPEIA demonstrate superior outcomes with daratumumab-based quadruplet and triplet combinations compared with standard regimens in transplant-eligible newly diagnosed multiple myeloma patients, particularly showing improved progression-free survival when daratumumab is added to VRd (bortezomib, lenalidomide, and dexamethasone) or VTd (bortezomib, thalidomide, and dexamethasone) backbones.

Panelists discuss how the CARTITUDE-4 and KarMMa-3 trials differ in their patient populations, study designs, and outcomes, providing crucial insights for clinicians choosing between cilta-cel and ide-cel chimeric antigen receptor T-cell therapies in relapsed/refractory multiple myeloma.

Panelists discuss the key factors that influence their institution's decision to utilize CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma and explain the next steps they would take if choosing CAR-T, including the rationale behind their decisions.

Panelists discuss how the updated results and longer follow-up from the AUGMENT-101 study of revumenib demonstrate its potential to improve outcomes in patients with relapsed/refractory KMT2Ar acute leukemia, offering a promising new option in this challenging subset of acute myeloid leukemia.

Panelists discuss how institutional challenges around chimeric antigen receptor T-cell therapy slot availability and waiting list management influence treatment sequencing decisions and affect subsequent therapy choices in earlier treatment lines for multiple myeloma.

Panelists discuss the evolving role of chimeric antigen receptor T-cell therapy in earlier lines of treatment for multiple myeloma, with a focus on upcoming advances for patients with standard-risk disease and the impact of multidisciplinary collaboration on improving patient care and outcomes.

Panelists discuss how a patient who is neutropenic is given supportive care with GCSF, as do patients who have prolonged neutropenia, then that patient will be on antibiotic and antifungal prophylaxis.

Panelists discuss advice for patients with myeloma considering chimeric antigen receptor T-cell therapy, drawing from their experiences to guide patients through the decision-making process and expectations for the treatment journey.

Panelists discuss how recent PET is reviewed with the patient, and there is evidence of near resolution of PET avid EMD lesions, though they will continue to monitor adenopathy – most suspicious for a reactive process. For patients treated with IVIG, the goal is to maintain a biological level of IgG at 400 mg/dL.

Panelists discuss how managing trastuzumab deruxtecan (T-DXd)–related toxicity and intolerance in later-line HER2+ breast cancer requires close monitoring, early detection of adverse effects like interstitial lung disease, and strategic adjustments to treatment regimens for improved patient safety and outcomes.

Panelists discuss the factors influencing the choice between isatuximab and daratumumab for induction therapy in transplant-eligible newly diagnosed multiple myeloma, as well as the role of dara-based quadruplet regimens as the standard of care and considerations for triplet regimens in specific patient populations.

Panelists discuss how metastatic site–specific outcomes with first-line therapies for clear cell renal cell carcinoma (ccRCC) provide insights into the efficacy of treatment strategies based on the location of metastases.